Astria Therapeutics Statistics
Share Statistics
Astria Therapeutics has 56.43M shares outstanding. The number of shares has increased by 101.23% in one year.
| Shares Outstanding | 56.43M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 2.75% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 48.26M |
| Failed to Deliver (FTD) Shares | 174 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 3.54M, so 6.27% of the outstanding shares have been sold short.
| Short Interest | 3.54M |
| Short % of Shares Out | 6.27% |
| Short % of Float | 7.34% |
| Short Ratio (days to cover) | 14.25 |
Valuation Ratios
The PE ratio is -3.17 and the forward PE ratio is -6.31.
| PE Ratio | -3.17 |
| Forward PE | -6.31 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.95 |
| P/FCF Ratio | -3.38 |
| PEG Ratio | n/a |
Enterprise Valuation
Astria Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 21.73, with a Debt / Equity ratio of 0.
| Current Ratio | 21.73 |
| Quick Ratio | 21.73 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.14 |
| Cash Flow / Debt | -208.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.3% and return on capital (ROIC) is -34.11%.
| Return on Equity (ROE) | -0.3% |
| Return on Assets (ROA) | -0.29% |
| Return on Capital (ROIC) | -34.11% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.24M |
| Employee Count | 59 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 52% in the last 52 weeks. The beta is 0.71, so Astria Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.71 |
| 52-Week Price Change | 52% |
| 50-Day Moving Average | 10.88 |
| 200-Day Moving Average | 11.02 |
| Relative Strength Index (RSI) | 43.17 |
| Average Volume (20 Days) | 337.95K |
Income Statement
In the last 12 months, Astria Therapeutics had revenue of $0 and earned -$72.89M in profits. Earnings per share was $-2.42.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -83.03M |
| Net Income | -72.89M |
| EBITDA | -83.03M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.42 |
Balance Sheet
The company has $175.53M in cash and $329.00K in debt, giving a net cash position of $175.20M.
| Cash & Cash Equivalents | 175.53M |
| Total Debt | 329.00K |
| Net Cash | 175.20M |
| Retained Earnings | -580.53M |
| Total Assets | 361.64M |
| Working Capital | 336.14M |
Cash Flow
In the last 12 months, operating cash flow was -$68.44M and capital expenditures -$25.00K, giving a free cash flow of -$68.47M.
| Operating Cash Flow | -68.44M |
| Capital Expenditures | -25.00K |
| Free Cash Flow | -68.47M |
| FCF Per Share | -2.27 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ATXS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -25.47% |
| FCF Yield | -12.77% |
Analyst Forecast
The average price target for ATXS is $27.5, which is 189.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $27.5 |
| Price Target Difference | 189.5% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Aug 20, 2021. It was a backward split with a ratio of 1:6.
| Last Split Date | Aug 20, 2021 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | 14.3 |
| Piotroski F-Score | 2 |